Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N1SH
|
|||
| Former ID |
DIB000626
|
|||
| Drug Name |
VX-15
|
|||
| Synonyms |
VX-15/2503; Plexin B1 antagonist (autoimmune disease/cancer), Vaccinex; Anti-CD100 MAb (autoimmune disease/cancer), Vaccinex;Anti-semaphorin 4D monoclonal antibody (autoimmune disease/cancer), Vaccinex
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Huntington disease [ICD-11: 8A01.10; ICD-10: G10; ICD-9: 294.1, 333.4] | Phase 2 | [1] | |
| Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 1 | [2] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1 | [3], [4] | ||
| Company |
Vaccinex Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutral endopeptidase (MME) | Target Info | Inhibitor | [4] |
| Semaphorin-4D (SEMA4D) | Target Info | . | [5] | |
| KEGG Pathway | Axon guidance | |||
| Renin-angiotensin system | ||||
| Hematopoietic cell lineage | ||||
| Protein digestion and absorption | ||||
| Alzheimer's disease | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| EGFR1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Panther Pathway | Axon guidance mediated by semaphorins | |||
| Reactome | Sema4D mediated inhibition of cell attachment and migration | |||
| Sema4D induced cell migration and growth-cone collapse | ||||
| Other semaphorin interactions | ||||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| WikiPathways | Semaphorin interactions | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Alzheimers Disease | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01764737) Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Soli... Clin Cancer Res. 2016 Feb 15;22(4):827-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.